Trulicity (dulaglutide) remains under patent, so M Care sources it through Eli Lilly's licensed Indian distribution channels rather than from generic manufacturers.
Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist pen from Eli Lilly. No FDA-licensed or EMA-authorised generic or biosimilar version exists at present. M Care, as a merchant exporter, sources Trulicity through licensed Indian distribution channels and dispatches it under validated 2-8C cold chain to importers across our served markets.
Dulaglutide exporter and bulk supplier from India.
M Care handles bulk and tender-volume Trulicity enquiries for hospital groups, MoH procurement desks and licensed wholesalers. Because dulaglutide is a patented biologic, every consignment traces back to Eli Lilly's own supply chain through the licensed Indian channel M Care sources from. We confirm batch documentation, cold-chain validation and destination import eligibility before dispatch, and we do not substitute another manufacturer's product for Trulicity.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist, Fc-fusion protein), sourced and documented for export.
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a fusion protein combining a modified GLP-1 peptide with a human IgG4 Fc fragment. It slows gastric emptying, stimulates glucose-dependent insulin secretion and suppresses glucagon release.
Trulicity is FDA-licensed as an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients aged 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Other licensed indications may apply per destination-country labelling.
Trulicity is supplied as a solution for injection in a single-dose pre-filled pen (0.5 mL). It requires continuous cold-chain storage at 2-8C from manufacture to point of use, with a limited room-temperature allowance for patient use only, never for bulk transit or storage.
Active ingredient
dulaglutide. GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist, Fc-fusion protein).
Forms and strengths
0.75 mg/0.5 mL; 1.5 mg/0.5 mL; 3 mg/0.5 mL; 4.5 mg/0.5 mL.
Indications
Once-weekly GLP-1 receptor agonist licensed for glycaemic control in type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
Administration
subcutaneous. Solution for injection in a single-dose pre-filled pen.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Hospital pharmacy and endocrinology departments, licensed pharmaceutical wholesalers, MoH diabetes-programme procurement desks in GCC and African markets, and private diabetes-care chains looking to add a GLP-1 option to formulary. Because Trulicity is a single-source patented brand, buyers are typically importers with an existing cold-chain distribution network rather than first-time biologic handlers.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on dulaglutide.
Dosing starts at 0.75 mg once weekly by subcutaneous injection. After at least 4 weeks, the dose may step up to 1.5 mg once weekly for additional glycaemic control, and if further control is needed it can be increased in 1.5 mg increments (to 3 mg, then 4.5 mg) after at least 4 weeks on the current dose, up to a maximum of 4.5 mg once weekly. This escalation pathway above 1.5 mg applies to adult patients only: for paediatric patients aged 10 years and older, the maximum recommended dose is 1.5 mg once weekly. The pen can be injected at any time of day, with or without food, and the injection day can be changed if the last dose was given at least 3 days before.
Missed-dose rule: if at least 3 days (72 hours) remain until the next scheduled dose, administer the missed dose as soon as possible. If fewer than 3 days remain, skip the missed dose and resume on the regular schedule. Do not double up.
Cold chain is the operational risk with this product. Pens are stored at 2-8C in the manufacturer's carton, protected from light, from dispatch through to the pharmacy fridge. Once removed from refrigeration, a pen may be kept below 30C for up to 14 days before it must be discarded; this room-temperature allowance is cumulative across however many times the pen leaves the fridge, and it is intended for the patient's use window, not for distributor-level storage or transit. Importers should plan validated 2-8C transport for every leg of the journey and treat the 14-day room-temperature window as a patient-facing buffer only.
Injection sites rotate between the abdomen, thigh and upper arm, with a different site used each week even within the same body area. No biosimilar or generic dulaglutide is licensed anywhere at present, so substitution is not a consideration for this product; supply continuity depends entirely on the authorised distribution chain.
The documentation pack a regulator actually asks for.
Because Trulicity is a biologic single-source brand, M Care's documentation chain centres on cold-chain integrity rather than manufacturing dossiers: temperature-logged, validated 2-8C transport lanes from the licensed Indian distribution point through to the importer's own cold storage, with batch and expiry traceability on every consignment. M Care holds CDSCO export licensure for pharmaceutical trade out of India and works to CTD/eCTD documentation standards for destination-country regulatory submissions where required.
On the product itself: Trulicity is an Eli Lilly originator biologic under patent protection, and no FDA-licensed or EMA-authorised biosimilar dulaglutide currently exists. M Care supplies genuine Trulicity sourced through Eli Lilly's own licensed Indian distribution channels, never a substitute manufacturer's version, and never implies a generic equivalent is available where none is licensed.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside dulaglutide.
Dapagliflozin metformin
Another diabetes & endocrine line ordered on the same formularies.
Empagliflozin
Another diabetes & endocrine line ordered on the same formularies.
Gliclazide
Another diabetes & endocrine line ordered on the same formularies.
All diabetes & endocrine
The full category listing for procurement desks.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for dulaglutide.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Dulaglutide supply, the specific questions.
Is there a generic or biosimilar version of Trulicity?
No. Dulaglutide remains under patent and no FDA-licensed or EMA-authorised biosimilar exists at present. Trulicity is currently a single-source brand, and M Care supplies only the genuine Eli Lilly product through licensed Indian distribution channels.
Can M Care supply Trulicity to my market?
Yes. M Care sources Trulicity through Eli Lilly's licensed Indian distribution channels and dispatches on validated cold-chain lanes. Import eligibility, registration status and any local licensing requirements are confirmed against your specific market before we quote, since Trulicity's own market authorisations vary by country.
What cold-chain conditions does Trulicity require in transit?
Trulicity must be kept at 2-8C, protected from light, in its original carton from dispatch through to the importer's cold storage. The 14-day below-30C allowance on the product label is a patient-use buffer, not a distribution or storage standard, so M Care plans validated 2-8C transport for the full shipment.
What strengths and pack format does Trulicity come in?
Trulicity is supplied as a solution for injection in single-dose pre-filled pens of 0.5 mL, in strengths of 0.75 mg, 1.5 mg, 3 mg and 4.5 mg.
What is Trulicity licensed for?
Trulicity is FDA-licensed as an adjunct to diet and exercise for glycaemic control in adults and children aged 10 and older with type 2 diabetes, and to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Paediatric dosing is capped at 1.5 mg once weekly; the higher strengths are for adult use. Destination-country labelling should be checked for any additional or narrower licensed indications.
Does M Care manufacture Trulicity or hold WHO-GMP certification for it?
No. M Care is a merchant exporter, not a manufacturer, and does not hold WHO-GMP or WHO-PQ status. We source Trulicity through Eli Lilly's own licensed Indian distribution channels and manage export documentation, cold-chain logistics and dispatch.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-26.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.